Comparing Clinical Outcomes of Tiotropium/ Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study

Meng Jer Hsieh, Ning Hung Chen, Shih Lung Cheng, Chi Wei Tao, Yu Feng Wei, Yao Kuang Wu, Ming Cheng Chan, Shih Feng Liu, Wu Huei Hsu, Tsung Ming Yang, Ming Shian Lin, Ching Lung Liu, Ping Hung Kuo, Ying Huang Tsai*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

8 Scopus citations

Abstract

Background: Long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA) combination therapy improved lung function and health-related quality-of-life and reduced exacerbation rates and dyspnea in symptomatic chronic obstructive pulmonary disease (COPD) patients. We compared the real-world effects of three fixed-dose LABA/LAMA combinations for COPD in Taiwan. Methods: This multicenter, retrospective study evaluated 1-year outcomes after LABA/LAMA combination therapy in patients with symptomatic COPD. Exacerbations and symptoms of COPD, lung functions, and therapy escalation were compared among patients using tiotropium/olodaterol, umeclidinium/vilanterol and indacaterol/glycopyrronium. Propensity score matching (PSM) was applied to balance the baseline characteristics. Results: Data of 1,617 patients were collected. After PSM, time to first moderate-to-severe COPD exacerbation was comparable among three groups, while the annualized rates of the exacerbation (episodes/patient/year) in patients receiving tiotropium/olodaterol (0.19) or umeclidinium/vilanterol (0.17) were significantly lower than those receiving indacaterol/glycopyrronium (0.38). COPD-related symptoms were stable over the treatment period, and there was no significant difference in the changes of symptom scores including CAT and mMRC among three groups at the end of the study period. Conclusion: This study presented valuable real-world outcome in terms of exacerbation and treatment response of COPD patients treated with fixed-dose LABA/LAMA regimens in Taiwan. The annualized rates of moderate-to-severe exacerbation in patients receiving tiotropium/olodaterol or umeclidinium/vilanterol were significantly lower than those receiving indacaterol/glycopyrronium, though the time to first moderate-to-severe exacerbation was similar among different fixed-dose LABA/LAMA combinations.

Original languageEnglish
Pages (from-to)967-976
Number of pages10
JournalInternational Journal of COPD
Volume17
DOIs
StatePublished - 2022

Bibliographical note

Publisher Copyright:
© 2022 Hsiehet al.

Keywords

  • LABA/LAMA therapy
  • Taiwan
  • chronic obstructive pulmonary disease
  • cohort study
  • indacaterol/glycopyrronium
  • moderate-to-severe exacerbation
  • propensity score matching
  • tiotropium/olodaterol
  • umeclidinium/vilanterol

Fingerprint

Dive into the research topics of 'Comparing Clinical Outcomes of Tiotropium/ Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study'. Together they form a unique fingerprint.

Cite this